KSR2: A Potential Drug Target and Biomarker for Cancer (G283455)

Target Name: KSR2

NCBI ID: G283455

KSR2

Other Name(s): Kinase suppressor of ras 2 | kinase suppressor of ras 2 | Kinase suppressor of Ras 2 | hKSR2 | KSR2_HUMAN

KSR2: A Potential Drug Target and Biomarker for Cancer

Kinase suppressor of ras 2 (KSR2) is a protein that plays a critical role in cell signaling pathways. It is a potent inhibitor of the RAS/MAPK signaling pathway, which is known to contribute to the development and progression of many types of cancer. KSR2 has also been identified as a potential drug target and biomarker for cancer.

The RAS/MAPK signaling pathway is a complex signaling pathway that regulates various cellular processes, including cell growth, differentiation, and survival. The RAS gene is a key regulator of this pathway, and it plays a central role in the development and maintenance of cancer . Activated RAS causes the formation of the RAS-MAPK complex, which consists of the protein kinase RAS and the adapter proteinMAPK. This complex regulates various cellular processes, including cell growth, differentiation, and survival.

KSR2 is a protein that is highly specific for the RAS/MAPK signaling pathway. It is a potent inhibitor of the RAS/MAPK complex, and it has been shown to inhibit the formation of the RAS-MAPK complex in cell culture. KSR2 works by binding to the MAPK protein and preventing it from interacting with the RAS protein. This inhibition of the RAS/MAPK signaling pathway has been shown to result in the inhibition of various cellular processes, including cell growth, differentiation, and survival.

KSR2 has also been shown to be a potential drug target for cancer. Cancer cells are highly dependent on the RAS/MAPK signaling pathway for cell growth, differentiation, and survival. Therefore, inhibiting this pathway is a promising strategy for the development of anti- cancer drugs. KSR2 has been shown to be a potential drug target by its ability to inhibit the RAS/MAPK complex, which is a critical step in the development and progression of cancer.

In addition to its potential as a drug target, KSR2 has also been identified as a potential biomarker for cancer. The RAS/MAPK signaling pathway is a critical pathway for the development and progression of many types of cancer, including pancreatic, breast, and colorectal cancers. Therefore, inhibiting this pathway is a promising strategy for the development of biomarkers for cancer. KSR2 has been shown to be a potential biomarker for cancer, as its levels have been shown to be altered in various types of cancer.

KSR2 has also been shown to have a positive impact on cancer cell survival and growth. In cancer cells, the RAS/MAPK signaling pathway is often activated, which results in the growth and survival of the cells. Therefore, inhibiting this pathway is a promising strategy for the development of anti-cancer drugs. KSR2 has been shown to have a positive impact on cancer cell survival and growth by inhibiting the RAS/MAPK signaling pathway.

In conclusion, KSR2 is a protein that plays a critical role in cell signaling pathways, particularly the RAS/MAPK signaling pathway. It is a potent inhibitor of the RAS/MAPK complex and has been shown to have a positive impact on cancer cell survival and growth. Therefore, KSR2 is a promising drug target and biomarker for cancer. Further research is needed to fully understand the role of KSR2 in cancer development and treatment.

Protein Name: Kinase Suppressor Of Ras 2

Functions: Location-regulated scaffold connecting MEK to RAF. Has very low protein kinase activity and can phosphorylate MAP2K1 at several Ser and Thr residues with very low efficiency (in vitro). Acts as MAP2K1/MEK1-dependent allosteric activator of BRAF; upon binding to MAP2K1/MEK1, dimerizes with BRAF and promotes BRAF-mediated phosphorylation of MAP2K1/MEK1 (PubMed:29433126). Interaction with BRAF enhances KSR2-mediated phosphorylation of MAP2K1 (in vitro). Blocks MAP3K8 kinase activity and MAP3K8-mediated signaling. Acts as a negative regulator of MAP3K3-mediated activation of ERK, JNK and NF-kappa-B pathways, inhibiting MAP3K3-mediated interleukin-8 production

The "KSR2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KSR2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets